55729-12-9

Upstream product

• 289505-10-8 (2R,3S,4R,5R,6S)-5-azido-6-(((1R,2R,3S,4R,6S)-4, 6-diazido-2,3-dihydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 534-47-4 Paromamine 
• 918800-34-7 C₅₃H₄₉N₉O₁₆ 
• 918800-25-6 C₂₄H₃₅N₉O₇ 
• 918800-26-7 Benzoic acid (2R,4aR,6S,7R,8R,8aS)-7-azido-6-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 918800-29-0 Benzoic acid (2S,3R,4R,5S,6R)-3-azido-2-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-5-hydroxy-6-hydroxymethyl-tetrahydro-pyran-4-yl ester 

Downstream Products

• 1141768-92-4 C₂₆H₄₇N₅O₁₆ 

Relevant academic research and scientific papers

Novel aminoglycosides and uses thereof in the treatment of genetic disorders

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low cytotoxicity and selectivity towards eukaryotic cells are provided. Also provided are processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations

A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.